MK-677 vs Sermorelin
Comparing oral ghrelin agonism with GHRH-based GH stimulation
Comparison summary
Overview
MK-677 vs Sermorelin compares two strategies for increasing endogenous GH signaling through different upstream pathways.
Mechanism comparison
This comparison focuses on ghrelin-receptor stimulation versus GHRH receptor stimulation.
Research comparison
The evidence should be weighed by route, endocrine physiology, human data depth, and body-composition relevance.
MK-677
Peptide
Type
ghrelin receptor agonist
Overview
MK-677 is a non-peptide ghrelin receptor agonist studied for GH and IGF-1 stimulation.
Clinical context
Users compare these compounds in hormone optimization, longevity, and body-recomposition contexts.
Use case comparison
The most relevant lens is hormone optimization through endogenous GH stimulation.
Safety considerations
Both can influence GH/IGF-1 pathways and require context-specific interpretation of endocrine risk.
Peptides studied
Stack studied
Ghrelin Drive Stack
GH Optimization Stack
Related studies
Bottom line
MK-677 is oral and ghrelin-based, while sermorelin is a classic GHRH analog with a cleaner pituitary-physiology narrative.